InnoCan Pharma
(OTCQB:INNPF)
$0.2081
0[0.00%]
At close: Apr 16
OverviewNewsEarningsGuidanceDividendsAnalyst RatingsInsider TradesShort Interest

InnoCan Pharma Stock (OTC:INNPF), Quotes and News Summary

InnoCan Pharma Stock (OTC: INNPF) stock price, news, charts, stock research, profile.

Open-
Close-
Volume / Avg.0 / 6.097K
Day Range- - -
52 Wk Range0.143 - 0.355
Market Cap$58.406M
P/E Ratio-
Dividend Yield-
ExchangeOTC
RSI
0
Short Interest-
Days to Cover11

Recent News

This Pharma Co. Kicks Off FDA Approval Process For CBD-Based Treatment Of Chronic Pain
Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) announced on Monday that it has submitted its letter of application for a Pre-IND meeting with the U.S. Food and Drug Administration (FDA, for its Liposome-Cannabidiol (LPT-CBD) injectable treatment of chronic pain. With the move, the company initiated the regulatory process with the FDA for the approval of its prolonged CBD release technology for human use.
Jelena Martinovic
534% Revenue Surge Unveiled By Israeli CBD-Focused Pharma Company, Exceeding Expectations
Innocan Pharma's 2023 earnings report: Revenue soars 534%, operating loss down 61%, $1.5M capital raise. CEO shares strategic vision.
Patricio Liddle
CBD-Focused Pharma Co. Innocan Reveals 433% YoY Increase In 2023 Revenue As It Pursues FDA Approval
Cannabinoid-focused pharmaceutical company Innocan Pharma Corp expects preliminary revenues of $4.89m in Q4 of fiscal 2023, representing a YoY increase of 331%. It said preliminary revenues are expected to be at least $13.6m for the whole of the fiscal year, a 433% YoY increase. Its subsidiary B.I. Sky Global drove the increase in sales. Innocan is currently pursuing FDA approval for its human pharmaceutical applications following successful pre-clinical trials, and the company expects pre-investigational new drug applications to be submitted to the FDA before the end of the month. Innocan has developed a long-lasting and therapeutic liposomal formulation for CBD called LPT Solution, which administers injectable CBD encapsulated in liposomes to achieve long-lasting therapeutic levels of CBD in the body. The company said the technology creates a more effective and prolonged therapeutic effect. Innocan plans to test the LPT platform on a new animal species in the near future.
Jelena Martinovic
-%

Financials

Quarterly
Annual
Name
Revenue
Change
Gross
Change
EBITDA
Change
EBIT
Change
Earnings
Change
About
Sector
Healthcare
Industry
N/A
InnoCan Pharma Corp is a pharmaceutical tech company that focuses on the development of several drug...
Show More

Compare

EPS worse than industry
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.
INNPF

FAQ

Q

How do I buy InnoCan Pharma (INNPF) stock?

A

You can purchase shares of InnoCan Pharma (OTCQB: INNPF) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are InnoCan Pharma's (INNPF) competitors?

A

There are no as such competitors for InnoCan Pharma.

Q

What is the target price for InnoCan Pharma (INNPF) stock?

A

There is no analysis for InnoCan Pharma.

Q

Current Stock Price for InnoCan Pharma (INNPF)?

A

The stock price for InnoCan Pharma (OTCQB: INNPF) is $0.241 last updated September 21, 2023 at 9:10 AM EDT.

Q

Does InnoCan Pharma (INNPF) pay a dividend?

A

There are no upcoming dividends for InnoCan Pharma.

Q

When is InnoCan Pharma (OTCQB:INNPF) reporting earnings?

A

InnoCan Pharma does not have any upcoming earnings scheduled.

Q

Is InnoCan Pharma (INNPF) going to split?

A

There is no upcoming split for InnoCan Pharma.

Q

What sector and industry does InnoCan Pharma (INNPF) operate in?

A

InnoCan Pharma is in the Healthcare sector and Drug Manufacturers—Specialty & Generic industry. They are listed on the OTCQB.